Please login to the form below

Not currently logged in
Email:
Password:

JAK inhibitors

This page shows the latest JAK inhibitors news and features for those working in and with pharma, biotech and healthcare.

Gilead and Galapagos JAK contender scores in RA trial

Gilead and Galapagos JAK contender scores in RA trial

Gilead and Galapagos JAK contender scores in RA trial. Trial adds to rivalry with AbbVie. ... Analysts are predicting a showdown between filgotinib and AbbVie’s rival, upadacitinib, as the next decisive event in the JAK inhibitor market.

Latest news

More from news
Approximately 2 fully matching, plus 19 partially matching documents found.

Latest Intelligence

  • Pharma deals during December 2012 Pharma deals during December 2012

    In return for this hefty premium, Gilead acquires a company with an annual cash burn of $30m developing orally active JAK 1 / JAK 2 kinase inhibitors and with a lead product, ... Company acquisition. JAK kinase inhibitors development company. 510. Sutro /

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • The Biosimilar Challenge

    Source: Adelphi Online Survey with N=55 Trust Pharmacists/CCG Commissioners/CCG HMM/HMOs. Theoretically cost-savings should be freeing up funds for new branded therapies such as JAK Inhibitors but

  • The Biosimilar Challenge

    Source: Adelphi Online Survey with N=55 Trust Pharmacists/CCG Commissioners/CCG HMM/HMOs. Theoretically cost-savings should be freeing up funds for new branded therapies such as JAK Inhibitors but

  • Brand leaders in RA will lose market share, predict rheumatologists

    JAK-inhibitors were the most commonly mentioned class, with Xeljanz the most frequently cited product.

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Resolute

Publicis Life Brands Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics